IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Precision Oncology Pionee | IDEAYA Biosciences leads in targeted cancer therapeutics, with darolutamide for uveal melanoma and IDE397 for MTAP-deficient cancers as key pipeline assets |
Financial Fortress | With $1.2 billion in cash reserves and a robust current ratio, IDEAYA is well-positioned to fund its ambitious R&D pipeline and potential commercialization efforts |
Catalysts on the Horizon | Anticipate pivotal clinical readouts, including darolutamide's PFS results in late 2025, and strategic R&D updates that could significantly impact IDEAYA's market valuation |
Analyst Optimism | RBC Capital Markets sets a $61 price target, reflecting confidence in IDEAYA's potential to revolutionize uveal melanoma treatment and expand its precision oncology portfolio |
Metrics to compare | IDYA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIDYAPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.1x | −1.0x | −0.5x | |
PEG Ratio | 0.09 | −0.05 | 0.00 | |
Price/Book | 2.1x | 2.3x | 2.6x | |
Price / LTM Sales | 289.2x | 8.9x | 3.3x | |
Upside (Analyst Target) | 99.1% | 318.8% | 43.5% | |
Fair Value Upside | Unlock | 7.6% | 6.8% | Unlock |